e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
E. C. Seyhan, H. Abali, S. N. Sökücü, L. Dalar, N. Büyükpinarbasili, S. Altin (Istanbul, Turkey)
Source:
Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Session:
Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Session type:
E-Communication Session
Number:
1439
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. C. Seyhan, H. Abali, S. N. Sökücü, L. Dalar, N. Büyükpinarbasili, S. Altin (Istanbul, Turkey). Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival. Eur Respir J 2009; 34: Suppl. 53, 1439
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
Source: Eur Respir J 2005; 25: 329-335
Year: 2005
Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 183-193
Year: 2011
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer
Source: Eur Respir J 2011; 38: 903-910
Year: 2011
Apelin expression is a prognostic factor in non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Vascular endothelial growth factor in sera of patients with non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 330s
Year: 2005
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019
Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
HER2/
Neu
overexpression as independent negative prognostic factor for non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept